Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study

Inflammatory Bowel Disease

Efficacy of Granulocyte and Monocyte Adsorptive Apheresis in Patients with Inflammatory Bowel Disease Showing Lost Response to Infliximab

J Crohns Colitis.

Yokoyama Y, Sawada K, Aoyama N, Yoshimura N, Sako M, Hirai F, Kashiwagi N, Suzuki Y

doi: 10.1093/ecco-jcc/jjaa051.

Inflammatory Bowel Disease

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study

Therap Adv Gastroenterol.

Grob L, Bluemel S, Biedermann L, Fournier N, Rossel JB, Vavricka SR, Zeitz J, Rogler G, Stallmach A, Scharl M

doi: 10.1177/1756284819895217.

Inflammatory Bowel Disease

Efficacy, tolerability and safety of low volume bowel preparations in Inflammatory Bowel Diseases: The French multicentre CLEAN study

J Crohns Colitis.

Briot C, Faure P, Parmentier AL, Nachury M, Trang C, Viennot S, Altwegg R, Bulois P, Thomassin L, Serrero M, Ah-Soune P, Gilletta C, Plastaras L, Simon M, Dray X, Caillo L, Del Tedesco E, Abitbol V, Zallot C, Degand T, Rossi V, Bonnaud G, Colin D, Morel B, Winkfield B, Danset JB, Filippi J, Amiot A, Attar A, Levy J, Peyrin-Biroulet L, Vuitton L; CLEAN study group

doi: 10.1093/ecco-jcc/jjz040.

COMMENTED

Inflammatory Bowel Disease

Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: A GETAID multicentre cohort study

J Crohns Colitis.

Caron B, Peyrin-Biroulet L, Pariente B, Bouhnik Y, Seksik P, Bouguen G, Caillo L, Laharie D, Carbonnel F, Altwegg R, Reenaers C, Serrero M, Trang-Poisson C, Nancey S, Filippi J, Abitbol V, Savoye G, Vuitton L, Viennot S, Fumery M, Reymond M, Bronowicki JP, Reimund JM, Amiot A, GETAID.

doi: 10.1093/ecco-jcc/jjz088.

Inflammatory Bowel Disease

Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study

doi: 10.1093/ecco-jcc/jjy183.

Inflammatory Bowel Disease

Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort

Eur J Gastroenterol Hepatol.

Godat S, Fournier N, Safroneeva E, Juillerat P, Nydegger A, Straumann A, Vavricka S, Biedermann L, Greuter T, Fraga M, Abdelrahman K, Hahnloser D, Sauter B, Rogler G, Michetti P, Schoepfer AM, Swiss IBD Cohort Study Group

doi: 10.1097/MEG.

Inflammatory Bowel Disease

Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort

Scand J Gastroenterol.

Buer LCT, Moum BA, Cvancarova M, Warren DJ, Bolstad N, Medhus AW, Høivik ML

doi: 10.1080/00365521.

RECOMMENDED

Inflammatory Bowel Disease

Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort - an Epi-IBD study

doi: 10.1111/jgh.14563.

RECOMMENDED

Inflammatory Bowel Disease

Effectiveness and safety of the switch from Remicade to CT-P13 in patients with inflammatory bowel disease

J Crohns Colitis.

Chaparro M, Garre A, Guerra Veloz MF, Vázquez JM, De Castro ML, Leo E, Rodriguez E, Carbajo AY, Riestra S, Jiménez I, Calvet X, Bujanda L, Rivero M, Gomollón F, Benítez JM, Bermejo F, Alcaide N, Gutiérrez A, Mañosa M, Iborra M, Lorente R, Rojas-Feria M, Barreiro-de Acosta M, Kolle L, Van Domselaar M, Amo V, Argüelles F, Ramírez E, Morell A, Bernardo D, Gisbert JP

doi: 10.1093/ecco-jcc/jjz070.

Related content

Efficacy of Granulocyte and Monocyte Adsorptive Apheresis in Patients with Inflammatory Bowel Disease Showing Lost Response to Infliximab

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study

Efficacy, tolerability and safety of low volume bowel preparations in Inflammatory Bowel Diseases: The French multicentre CLEAN study

Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: A GETAID multicentre cohort study

Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study

Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort

Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort

Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort - an Epi-IBD study

Effectiveness and safety of the switch from Remicade to CT-P13 in patients with inflammatory bowel disease